Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ATNM 
Actinium Pharmaceuticals Inc (ATNM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/04/2025: ATNM (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 63.48% | Avg. Invested days 37 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 40.24M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 989422 | Beta -0.27 | 52 Weeks Range 1.03 - 10.24 | Updated Date 04/5/2025 |
52 Weeks Range 1.03 - 10.24 | Updated Date 04/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-27 | When After Market | Estimate -0.39 | Actual -0.21 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.25% | Return on Equity (TTM) -110.63% |
Valuation
Trailing PE - | Forward PE 6.84 | Enterprise Value -31088301 | Price to Sales(TTM) 652.71 |
Enterprise Value -31088301 | Price to Sales(TTM) 652.71 | ||
Enterprise Value to Revenue 1726.07 | Enterprise Value to EBITDA -3.62 | Shares Outstanding 31195900 | Shares Floating 31037728 |
Shares Outstanding 31195900 | Shares Floating 31037728 | ||
Percent Insiders 1.79 | Percent Institutions 29.26 |
Analyst Ratings
Rating 4.2 | Target Price 5 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Actinium Pharmaceuticals Inc
Company Overview
History and Background
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of innovative targeted radiotherapies for advanced cancers. Founded in 2005, the company has focused on developing its Alpha Particle Immunotherapy (APIT) platform.
Core Business Areas
- Therapeutic Development: Focuses on developing and commercializing targeted radiotherapies, primarily using Actinium-225 (Ac-225).
- API Supply: Actinium also aims to have in-house supply of API Actinium-225.
Leadership and Structure
Sandesh Seth is the Chairman and CEO. The company has a board of directors and a management team overseeing research, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- Iomab-B: Iomab-B is Actinium's lead product candidate in pivotal Phase 3 trial for patients with active relapsed or refractory acute myeloid leukemia (r/r AML) who are age 55 and older. Currently under FDA review. Competitors include standard chemotherapy regimens, stem cell transplantation (if eligible), and other emerging AML therapies from companies like Jazz Pharmaceuticals and Agios Pharmaceuticals.
Market Dynamics
Industry Overview
The radiopharmaceutical market is experiencing growth driven by advancements in targeted therapies and increasing demand for personalized medicine in oncology. The industry is characterized by innovation, strategic collaborations, and regulatory scrutiny.
Positioning
Actinium is positioned as a developer of targeted radiotherapies, specifically focused on using Ac-225. Its competitive advantage lies in its APIT platform and its lead product candidate Iomab-B.
Total Addressable Market (TAM)
The TAM for targeted radiotherapies in oncology is estimated to be in the billions of dollars. Actinium is positioned to capture a share of this market with Iomab-B and other potential products.
Upturn SWOT Analysis
Strengths
- Proprietary APIT platform
- Lead product candidate Iomab-B in late-stage development
- Experienced management team
- Strong intellectual property position
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on successful clinical trials and regulatory approvals
- Limited commercialization experience
Opportunities
- Expansion of APIT platform to other cancer targets
- Strategic collaborations with larger pharmaceutical companies
- Potential for breakthrough therapy designation and accelerated approval pathways
- Growing demand for targeted radiotherapies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Clinical trial failures
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- ITMN
- BAYRY
- NVS
Competitive Landscape
Actinium Pharmaceuticals operates in a highly competitive pharmaceutical landscape, facing challenges from established players with larger resources and broader product portfolios. Actinium's competitive advantage lies in its specific radiopharmaceutical technology and pipeline, which could offer advantages in certain niche applications, particularly in targeted cancer therapies. However, the company needs to demonstrate clinical efficacy and secure regulatory approvals to effectively compete and capture market share.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is driven by the progression of Iomab-B through clinical trials.
Future Projections: Future growth depends on successful commercialization of Iomab-B and expansion of the APIT platform.
Recent Initiatives: Focus on completing the Iomab-B clinical trials, and potential FDA submission, as well as, exploring other opportunities for Ac-225
Summary
Actinium Pharmaceuticals is a biopharmaceutical company with a focus on targeted radiotherapies. Its lead product candidate, Iomab-B, is in late-stage clinical development and represents a significant opportunity. The company faces challenges related to funding, competition, and regulatory hurdles. Successful commercialization of Iomab-B and expansion of the APIT platform will be critical for future growth. The company needs to secure additional funding to continue its operations.
Similar Companies
NVS
Novartis AG ADR
NVS
Novartis AG ADR
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Actinium Pharmaceuticals Inc
Exchange NYSE MKT | Headquaters New York, NY, United States | ||
IPO Launch date 2012-12-27 | Chairman & CEO Mr. Sandesh C. Seth M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | Website https://www.actiniumpharma.com |
Full time employees 37 | Website https://www.actiniumpharma.com | ||
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.